Orange Book product · Brand (NDA)
APLENZIN
BUPROPION HYDROBROMIDE
At a glance
Apr 23, 2008
Approved
Brand (NDA)
Application
Not listed
TE code
8
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Apr 23, 2008
18 yr 5 mo ago
Today
Patent 7241805 expires
Listed drug product patent expiration.
Jun 27, 2026
in 8 d
Patent 7569610 expires
Listed method-of-use patent (U-997) expiration.
Jun 27, 2026
in 8 d
Patent 7572935 expires
Listed drug product patent expiration.
Jun 27, 2026
in 8 d
Patent 7585897 expires
Listed drug product patent expiration.
Jun 27, 2026
in 8 d
Patent 7645802 expires
Listed drug product patent expiration.
Jun 27, 2026
in 8 d
Patent 7649019 expires
Listed drug product patent expiration.
Jun 27, 2026
in 8 d
Patent 7662407 expires
Listed drug product patent expiration.
Jun 27, 2026
in 8 d
Patent 7671094 expires
Listed drug product patent expiration.
Jun 27, 2026
in 8 d
Pharmaceutical detail
Active ingredient
BUPROPION HYDROBROMIDE
Strength
174MG
Dosage form
TABLET, EXTENDED RELEASE
Route
ORAL
TE code
Not listed
Application
NDA 022108
Product number
001
Marketing status
RX
Reference listed drug (RLD)
Yes
Reference standard (RS)
No
Active-ingredient family
View full familyThis is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
Listed patents (8)
| Patent | Expires | In | Type |
|---|---|---|---|
| 7241805 | Jun 27, 2026 | in 8 d | Product |
| 7569610 | Jun 27, 2026 | in 8 d | U-997 |
| 7572935 | Jun 27, 2026 | in 8 d | Product |
| 7585897 | Jun 27, 2026 | in 8 d | Product |
| 7645802 | Jun 27, 2026 | in 8 d | Product |
| 7649019 | Jun 27, 2026 | in 8 d | Product |
| 7662407 | Jun 27, 2026 | in 8 d | Product |
| 7671094 | Jun 27, 2026 | in 8 d | Product |
